Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Inflammation × Dexmedetomidine × Clear all

Phase

Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain, Postoperative 3 Neoplasms 2 Agnosia 2 Thyroid Neoplasms 1 Postoperative Analgesia 1 Pain, Intractable 1 Neoplasm Metastasis 1 Inflammation 1

Interventions

Etanercept 1 Dexmedetomidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04106999 2022-11-03

Dexmedetomidine and HIPEC

University of British Columbia

Phase 2/3 Unknown

Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡